文献速递乳腺癌

BIG 1-98研究中胆固醇、降胆固醇药物使用与乳腺癌结局

Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.
PubMed 文献 · J Clin Oncol · 2017-02-13

BIG 1-98随机III期双盲试验纳入8010例绝经后早期激素受体阳性浸润性乳腺癌女性,分析内分泌治疗期间启动降胆固醇药物(CLM)与结局的关系。共789例在内分泌治疗期间启动CLM,启动CLM与无病生存期改善(HR 0.79)、无乳腺癌间期改善(HR 0.76)和无远处复发间期改善(HR 0.74)相关。作者建议这些观察性结果需在前瞻性随机试验中验证。

要点

  • 他莫昔芬治疗期间胆固醇水平降低。
  • 内分泌治疗期间启动CLM与无病生存期改善相关(HR 0.79,95%CI 0.66-0.95,P=.01)。
  • 作者建议这些观察性结果需在前瞻性随机试验中验证。

核心结论

  • 辅助内分泌治疗期间使用降胆固醇药物可能在预防激素受体阳性早期乳腺癌复发中发挥作用。
  • 作者建议这些观察性结果需在前瞻性随机试验中验证。

研究设计与样本

  • BIG 1-98是一项随机、III期、双盲试验,1998年至2003年纳入8010例绝经后早期激素受体阳性浸润性乳腺癌女性。
  • 在研究入组时及至5.5年每6个月测量总胆固醇全身水平和降胆固醇药物使用情况。
  • 采用累积发生率函数描述竞争风险下CLM的启动,采用边际结构Cox比例风险模型分析内分泌治疗期间启动CLM与结局的关系。

主要发现

  • 他莫昔芬治疗期间胆固醇水平降低。
  • 789例在内分泌治疗期间启动CLM的患者中,多数来自来曲唑单药组(n=318),其次为序贯他莫昔芬-来曲唑组(n=189)、来曲唑-他莫昔芬组(n=176)和他莫昔芬单药组(n=106)。
  • 内分泌治疗期间启动CLM与无病生存期改善相关(HR 0.79;95%CI 0.66-0.95;P=.01)。
  • 内分泌治疗期间启动CLM与无乳腺癌间期改善相关(HR 0.76;95%CI 0.60-0.97;P=.02)。
  • 内分泌治疗期间启动CLM与无远处复发间期改善相关(HR 0.74;95%CI 0.56-0.97;P=.03)。

临床怎么用

  • 作者建议这些观察性结果需在前瞻性随机试验中验证。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Cholesterol-lowering medication (CLM) has been reported to have a role in preventing breast cancer recurrence. CLM may attenuate signaling through the estrogen receptor by reducing levels of the estrogenic cholesterol metabolite 27-hydroxycholesterol. The impact of endocrine treatment on cholesterol levels and hypercholesterolemia per se may counteract the intended effect of aromatase inhibitors. Patients and Methods The Breast International Group (BIG) conducted a randomized, phase III, double-blind trial, BIG 1-98, which enrolled 8,010 postmenopausal women with early-stage, hormone receptor-positive invasive breast cancer from 1998 to 2003. Systemic levels of total cholesterol and use of CLM were measured at study entry and every 6 months up to 5.5 years. Cumulative incidence functions were used to describe the initiation of CLM in the presence of competing risks. Marginal structural Cox proportional hazards modeling investigated the relationships between initiation of CLM during endocrine therapy and outcome. Three time-to-event end points were considered: disease-free-survival, breast cancer-free interval, and distant recurrence-free interval. Results Cholesterol levels were reduced during tamoxifen therapy. Of 789 patients who initiated CLM during endocrine therapy, the majority came from the letrozole monotherapy arm (n = 318), followed by sequential tamoxifen-letrozole (n = 189), letrozole-tamoxifen (n = 176), and tamoxifen monotherapy (n = 106). Initiation of CLM during endocrine therapy was related to improved disease-free-survival (hazard ratio [HR], 0.79; 95% CI, 0.66 to 0.95; P = .01), breast cancer-free interval (HR, 0.76; 95% CI, 0.60 to 0.97; P = .02), and distant recurrence-free interval (HR, 0.74; 95% CI, 0.56 to 0.97; P = .03). Conclusion Cholesterol-lowering medication during adjuvant endocrine therapy may have a role in preventing breast cancer recurrence in hormone receptor-positive early-stage breast cancer. We recommend that these observational results be addressed in prospective randomized trials.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Borgquist S, Giobbie-Hurder A, Ahern TP, et al. Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. J Clin Oncol. 2017. PMID: 28380313. doi:10.1200/JCO.2016.70.3116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。